The choppy/consolidating (or perhaps worse) market conditions sometimes give the impression that growth plays do not exist, but that is not the case, and one growth company worth reviewing is Elan Corp. Note: Elan is appropriate only for investors who can tolerate high-risk.
Elan Corp. (NYSE: ELN) is a neuroscience-based technology company focused on discovering, developing, manufacturing and marketing advanced therapies in neurology, autoimmune diseases and severe pain.
Analysts sees 33-40% revenue growth for Elan in 2008 after likely 30-35% growth in 2007.
Analysts also like Elan's ramping sales for drug Tysabri for multiple sclerosis and Crohn's disease; they are also hopeful about the company's Alzheimer drug, bapineuzmab, currently in trials.
Elan Corp. (NYSE: ELN) is a neuroscience-based technology company focused on discovering, developing, manufacturing and marketing advanced therapies in neurology, autoimmune diseases and severe pain.
Analysts sees 33-40% revenue growth for Elan in 2008 after likely 30-35% growth in 2007.
Analysts also like Elan's ramping sales for drug Tysabri for multiple sclerosis and Crohn's disease; they are also hopeful about the company's Alzheimer drug, bapineuzmab, currently in trials.
Before the bell: Futures sharply lower on Dubai's debt problems
Will Rich Ross really have a positive impact on Disney's movie operations?
Consumers sick of recession, may spend extra on holidays
